Prednicare
Active substance
ATC code
Species
Dogs and Cats
Indications
As an anti-inflammatory and anti-allergic agent for use in dogs and cats.
Dose to be administered and administration route
For oral administration.
Single dose treatment may be appropriate for some specific conditions (anaphylaxis, etc), but for more general treatment, treatment may be given for one to three weeks at doses between:
DOGS: 0.1-2.0 mg/kg/day
CATS: 0.1-2.0 mg/kg/day
The lowest effective dose must be used. Treatment should not be withdrawn suddenly. Problems of adrenal insufficiency should be minimised by dosing on alternate days, dosing to coincide with the endogenous cortisol peak (i.e. in the morning with regard to dogs and in the evening with regard to cats) and a gradual reduction in dosage.
For the treatment of cats and dogs with tumours responsive to corticosteroid therapy, the balance between the risks of therapy and the benefits of treatment may justify larger doses. In such cases, doses between 20 mg/m² every other day and 60 mg/m²/day have been found to be useful. (Dose is related to the animal’s estimated body surface area, in square metres.)
Adverse reactions
Anti-inflammatory steroids are known to exert a wide range of side effects. Very commonly, Cushingoid symptoms involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g., redistribution of body fat, muscle weakness and osteoporosis may occur Based on post marketing experience and complementary data, lethargy, diarrhoea and emesis have been observed very rarely.
During therapy, very commonly, effective doses suppress the Hypothalamic-Pituitary-Adrenal axis. Following cessation of treatment, symptoms of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations.
Systemically acting corticosteroids rarely can cause polyuria, polydipsia and polyphagia, particularly during the early stages of therapy. Some corticosteroids may cause sodium and water retention and hypokalaemia in long term use. Systemic corticosteroids have caused deposition of calcium in the skin (calcinosis cutis).
Corticosteroids rarely can delay wound healing and the immunosuppressant actions may weaken resistance to or exacerbate existing infections.
Gastrointestinal ulceration has been reported very rarely in animals treated with corticosteroids and usually with the concurrent use of non-steroidal anti-inflammatory drugs (see section 4.8).
Steroids very rarely may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 32742/4034 |
